Moneycontrol PRO
HomeNewsTrendsHealthCentre asks states to keep an eye on emerging COVID-19 clusters as BA.4, BA.5 detected from random samples

Centre asks states to keep an eye on emerging COVID-19 clusters as BA.4, BA.5 detected from random samples

While the BA.4 strain has been confirmed in Telangana and Tamil Nadu, BA.5 has been found only in Telangana so far. Both patients are showing mild symptoms

May 25, 2022 / 10:31 IST

As India’s COVID-19 genome surveillance project confirms the presence of Omicron subvariants, BA.4 and BA.5, in the country, the Centre has asked states to keep an eye on potential clusters of coronavirus infections and disease severity patterns based on hospitalisation rates.

The BA.4 and BA.5 variants were found to lead a fifth wave of COVID-19 in South Africa recently before being detected in several other countries.

The instructions come as India reported 2,124 new COVID-19 cases on May 24, over 26 percent more than the infection reported on the previous day, while active cases, too, increased on the second consecutive day.

In a bulletin dated May 21, which was released on May 23, the Indian SARS-CoV-2 Genomics Consortium (INSACOG) said that a 19- year-old female in Tamil Nadu has been found infected with the BA.4 variant of SARS-CoV-2.

“The patient has shown only mild clinical symptoms and has been fully vaccinated. The patient had no travel history. Before this, a South African traveller was reported positive for the BA.4 variant on arrival at Hyderabad airport,” the bulletin said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The bulletin added that an 80-year-old man in Telangana tested positive for the BA.5 variant. This patient, too, was fully vaccinated and had no travel history. He was only mildly symptomatic, according to INSACOG. It added that contact tracing of patients detected with BA.4. and BA.5 is being undertaken as a precautionary measure.

“These variants have not been associated with disease severity or increased hospitalisation,” the project led by the National Centre for Disease Control under the Union health ministry clarified.

Omicron subvariants already in the community

Scientists attached with INSACOG said that as patients with the new subvariants have been found without any international travel history, it suggested community transmission of these strains already.

“These subvariants have been found in random samples sent by states for whole genome sequencing and they show that these strains are already circulating in the community,” said an INSACOG scientist.

Previously, the consortium has also confirmed the presence of BA.2.12.1 in India. This strain was leading a surge in COVID-19 cases in parts of the US in April.

No major concern for India

Experts, meanwhile, sought to allay fears related to a possible surge in cases in India but underlined the need to remain vigilant.

“There are no major concerns based on what we know so far as most people in India have both recovered from the infection as well as have been vaccinated. This ensures that the risk for severe disease in the country is among the lowest worldwide,” said Anurag Agarwal, a biologist with Ashoka University. Till recently, he headed the CSIR-Institute for Genomics and Integrative Biology, an INSACOG partner.

“Further we had a recent BA.2 wave, and BA.4 and BA.5 are antigenically closer to BA.2 than BA.1,” he said, referring to the omicron wave in India in January this year, in which BA.2 was the dominant strain.

Immunologist Dipyaman Ganguly, who is attached with the CSIR-Indian Institute of Chemical Biology, said that genetic surveillance is always necessary not only to track BA.4 or BA.5, but also to keep a vigil for new variants.

“But public scare is not justified with regard to BA.4 or BA.5, as the clinical features associated with these variants are far from too severe,” he said.

 

Sumi Sukanya Dutta
Sumi Sukanya Dutta
first published: May 25, 2022 10:31 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347